Literature DB >> 12744720

Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues.

John D Hooper1, Luisa Campagnolo, Goodarz Goodarzi, Tony N Truong, Heidi Stuhlmann, James P Quigley.   

Abstract

We report the identification and characterization of mouse matriptase-2 (m-matriptase-2), an 811-amino-acid protein composed of an N-terminal cytoplasmic domain, a membrane-spanning domain, two CUB (complement protein subcomponents C1r/C1s, urchin embryonic growth factor and bone morphogenetic protein 1) domains, three LDLR (low-density-lipoprotein receptor class A) domains and a C-terminal serine-protease domain. All m-matriptase-2 protein domain boundaries corresponded with intron/exon junctions of the encoding gene, which spans approx. 29 kb and comprises 18 exons. Matriptase-2 is highly conserved in human, mouse and rat, with the rat matriptase-2 gene ( r-maltriptase-2 ) predicted to encode transmembrane and soluble isoforms. Western-blot analysis indicated that m-matriptase-2 migrates close to its theoretical molecular mass of 91 kDa, and immunofluorescence analysis was consistent with the proposed surface membrane localization of this protein. Reverse-transcription PCR and in-situ -hybridization analysis indicated that m-matriptase-2 expression overlaps with the distribution of mouse hepsin (m-hepsin, a cell-surface serine protease identified in hepatoma cells) in adult tissues and during embryonic development. In adult tissues both are expressed at highest levels in liver, kidney and uterus. During embryogenesis m-matriptase-2 expression peaked between days 12.5 and 15.5. m-hepsin expression was biphasic, with peaks at day 7.5 to 8.5 and again between days 12.5 and 15.5. In situ hybridization of embryonic tissues indicated abundant expression of both m-matriptase-2 and m-hepsin in the developing liver and at lower levels in developing pharyngo-tympanic tubes. While m-hepsin was detected in the residual embryonic yolk sac and with lower intensity in lung, heart, gastrointestinal tract, developing kidney tubules and epithelium of the oral cavity, m-matriptase-2 was absent in these tissues, but strongly expressed within the nasal cavity by olfactory epithelial cells. Mechanistic insight into the potential role of this new transmembrane serine protease is provided by its novel expression profile in embryonic and adult mouse.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744720      PMCID: PMC1223555          DOI: 10.1042/BJ20030390

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  58 in total

1.  The PROSITE database, its status in 2002.

Authors:  Laurent Falquet; Marco Pagni; Philipp Bucher; Nicolas Hulo; Christian J A Sigrist; Kay Hofmann; Amos Bairoch
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes.

Authors:  Faye Wu; Wei Yan; Junliang Pan; John Morser; Qingyu Wu
Journal:  J Biol Chem       Date:  2002-03-07       Impact factor: 5.157

3.  Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue.

Authors:  T Takeuchi; M A Shuman; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis.

Authors:  Karin List; Christian C Haudenschild; Roman Szabo; WanJun Chen; Sharon M Wahl; William Swaim; Lars H Engelholm; Niels Behrendt; Thomas H Bugge
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

5.  Spinesin/TMPRSS5, a novel transmembrane serine protease, cloned from human spinal cord.

Authors:  Nozomi Yamaguchi; Akira Okui; Tatsuo Yamada; Hiroshi Nakazato; Shinichi Mitsui
Journal:  J Biol Chem       Date:  2001-12-12       Impact factor: 5.157

6.  Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase.

Authors:  Rainer Friedrich; Pablo Fuentes-Prior; Edgar Ong; Gary Coombs; Michael Hunter; Ryan Oehler; Diane Pierson; Richard Gonzalez; Robert Huber; Wolfram Bode; Edwin L Madison
Journal:  J Biol Chem       Date:  2001-11-05       Impact factor: 5.157

7.  N-terminal processing is essential for release of epithin, a mouse type II membrane serine protease.

Authors:  E G Cho; M G Kim; C Kim; S R Kim; I S Seong; C Chung; R H Schwartz; D Park
Journal:  J Biol Chem       Date:  2001-09-20       Impact factor: 5.157

8.  Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.

Authors:  Michael D Oberst; Michael D Johnson; Robert B Dickson; Chen-Yong Lin; Baljit Singh; Moira Stewart; Alastair Williams; Awatif al-Nafussi; John F Smyth; Hani Gabra; Grant C Sellar
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

9.  Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins.

Authors:  Gloria Velasco; Santiago Cal; Victor Quesada; Luis M Sánchez; Carlos López-Otín
Journal:  J Biol Chem       Date:  2002-07-30       Impact factor: 5.157

10.  Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue.

Authors:  Thomas Ernst; Manfred Hergenhahn; Marc Kenzelmann; Clemens D Cohen; Mahnaz Bonrouhi; Annette Weninger; Ralf Klären; Elisabeth F Gröne; Manfred Wiesel; Christof Güdemann; Jens Küster; Winfried Schott; Gerd Staehler; Matthias Kretzler; Monica Hollstein; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

View more
  29 in total

Review 1.  Membrane-anchored serine proteases in vertebrate cell and developmental biology.

Authors:  Roman Szabo; Thomas H Bugge
Journal:  Annu Rev Cell Dev Biol       Date:  2011-06-29       Impact factor: 13.827

2.  Essential role of endocytosis of the type II transmembrane serine protease TMPRSS6 in regulating its functionality.

Authors:  François Béliveau; Cédric Brulé; Antoine Désilets; Brandon Zimmerman; Stéphane A Laporte; Christine L Lavoie; Richard Leduc
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

3.  Common TMPRSS6 mutations and iron, erythrocyte, and pica phenotypes in 48 women with iron deficiency or depletion.

Authors:  Pauline L Lee; J Clayborn Barton; Peter L Khaw; Sarah Y Bhattacharjee; James C Barton
Journal:  Blood Cells Mol Dis       Date:  2012-01-21       Impact factor: 3.039

4.  Proprotein convertase PC7 enhances the activation of the EGF receptor pathway through processing of the EGF precursor.

Authors:  Estelle Rousselet; Suzanne Benjannet; Edwidge Marcinkiewicz; Marie-Claude Asselin; Claude Lazure; Nabil G Seidah
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

5.  N-glycosylation is required for matriptase-2 autoactivation and ectodomain shedding.

Authors:  Jiang Jiang; Jianfeng Yang; Ping Feng; Bin Zuo; Ningzheng Dong; Qingyu Wu; Yang He
Journal:  J Biol Chem       Date:  2014-05-27       Impact factor: 5.157

Review 6.  Matriptase: potent proteolysis on the cell surface.

Authors:  Karin List; Thomas H Bugge; Roman Szabo
Journal:  Mol Med       Date:  2006 Jan-Mar       Impact factor: 6.354

7.  Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.

Authors:  Karin List; Roman Szabo; Alfredo Molinolo; Virote Sriuranpong; Vivien Redeye; Tricia Murdock; Beth Burke; Boye S Nielsen; J Silvio Gutkind; Thomas H Bugge
Journal:  Genes Dev       Date:  2005-08-15       Impact factor: 11.361

Review 8.  Iron-refractory iron deficiency anemia: new molecular mechanisms.

Authors:  Yujie Cui; Qingyu Wu; Yiqing Zhou
Journal:  Kidney Int       Date:  2009-09-23       Impact factor: 10.612

9.  Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.

Authors:  Shuling Guo; Carla Casu; Sara Gardenghi; Sheri Booten; Mariam Aghajan; Raechel Peralta; Andy Watt; Sue Freier; Brett P Monia; Stefano Rivella
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

10.  A novel TMPRSS6 mutation that prevents protease auto-activation causes IRIDA.

Authors:  Sandro Altamura; Flavia D'Alessio; Barbara Selle; Martina U Muckenthaler
Journal:  Biochem J       Date:  2010-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.